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1. Data {#sec1}
=======

[Fig. 1](#fig1){ref-type="fig"} includes a clinician-facing action recommendation report with two versions -- one for a negative result which requires no action, and the other for a positive result, which suggests ordering an echocardiogram. [Fig. 2](#fig2){ref-type="fig"} is a sample email alert to clinicians when a positive screening result is detected. [Fig. 3](#fig3){ref-type="fig"} is the baseline survey that will be administered to clinicians at the time of enrolment. [Fig. 4](#fig4){ref-type="fig"} is the end-of-study survey that will be administered to clinicians in the intervention group at the end of the trial \[[@bib1]\].Fig. 1Sample clinician-facing report for ECG AI guided screening for low ejection fraction (EAGLE).Fig. 1Fig. 2Sample email alert to clinicians when a positive screening result is detected.Fig. 2Fig. 3Clinician baseline survey.Fig. 3Fig. 4Clinician end-of-study survey.Fig. 4

2. Experimental design, materials, and methods {#sec2}
==============================================

The clinician-facing action recommendation report was developed over a period of four months (December 2018--March 2019). A multi-disciplinary team developed a prototype of the report using a user-centered iterative approach. The principal investigators of the project (a health services researcher and a cardiologist) drafted an initial prototype. The investigative team then identified major groups of clinicians who frequently order ECG (i.e., those in primary care, cardiology, emergency medicine, and anesthesiology) and introduced the tool to the leadership of these departments during face-to-face meetings. At these stakeholder meetings, the investigative team got a better understanding of their needs and solicited feedback on the new tool and the design of the report. The investigative team also asked the department leaders to suggest 3--5 practicing clinicians in each department to participate in the subsequent testing and refinement of the prototype. Two designers worked with practicing clinicians to conduct interviews and workflow observations. A series of prototypes were developed, tested, and revised based on these clinicians\' feedback. The investigative team met regularly to discuss the iterations of the prototype and the clinicians\' feedback. The prototype was also tested with five clinicians using real patient data and was then finalized based on the feedback. Other trial materials were developed by the multi-disciplinary team including physicians from cardiology and primary care, health services researchers, statisticians, and a study coordinator.
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